Yuflyma Injection Dosage

Generic name: adalimumab 40mg in 0.4mL
Dosage form: injection
Drug class: TNF alfa inhibitors

Medically reviewed by Drugs.com. Last updated on Jan 2, 2024.

Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

The recommended subcutaneous dosage of YUFLYMA for adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other week. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti- inflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with YUFLYMA. In the treatment of RA, some patients not taking concomitant MTX may derive additional benefit from increasing the dosage of YUFLYMA to 40 mg every week or 80 mg every other week.

Juvenile Idiopathic Arthritis

The recommended subcutaneous dosage of YUFLYMA for patients 2 years of age and older with polyarticular juvenile idiopathic arthritis (JIA) is based on weight as shown below. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment with YUFLYMA.

Pediatric Weight (2 years of age and older)	Recommended Dosage
15 kg (33 lbs) to less than 30 kg (66 lbs)	20 mg every other week
30 kg (66 lbs) and greater	40 mg every other week

There is no dosage form for YUFLYMA that allows weight-based dosing for pediatric patients below 15 kg.

Adalimumab products have not been studied in patients with polyarticular JIA less than 2 years of age or in patients with a weight below 10 kg.

Crohn's Disease

Adults

The recommended subcutaneous dosage of YUFLYMA for adult patients with Crohn's disease (CD) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a dosage of 40 mg every other week. Aminosalicylates and/or corticosteroids may be continued during treatment with YUFLYMA. Azathioprine, 6- mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] or MTX may be continued during treatment with YUFLYMA if necessary.

Pediatrics

The recommended subcutaneous dosage of YUFLYMA for pediatric patients 6 years of age and older with Crohn's disease (CD) is based on body weight as shown below:

Pediatric Weight	Recommended Dosage
Pediatric Weight	Days 1 through 15	Starting on Day 29
17 kg (37 lbs) to less than 40 kg (88 lbs)	Day 1: 80 mg Day 15: 40 mg	20 mg every other week
40 kg (88 lbs) and greater	Day 1: 160 mg (single dose or split over two consecutive days) Day 15: 80 mg	40 mg every other week

Ulcerative Colitis

Adults

The recommended subcutaneous dosage of YUFLYMA for adult patients with ulcerative colitis (UC) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) continue with a dosage of 40 mg every other week.

Discontinue YUFLYMA in adult patients without evidence of clinical remission by eight weeks (Day 57) of therapy. Aminosalicylates and/or corticosteroids may be continued during treatment with YUFLYMA. Azathioprine and 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] may be continued during treatment with YUFLYMA if necessary.

Plaque Psoriasis or Adult Uveitis

The recommended subcutaneous dosage of YUFLYMA for adult patients with plaque psoriasis (Ps) or Uveitis (UV) is an initial dose of 80 mg, followed by 40 mg given every other week starting one week after the initial dose. The use of adalimumab products in moderate to severe chronic Ps beyond one year has not been evaluated in controlled clinical studies.

Hidradenitis Suppurativa

Adults

The recommended subcutaneous dosage of YUFLYMA for adult patients with hidradenitis suppurativa (HS) is an initial dose of 160 mg (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Begin 40 mg weekly or 80 mg every other week dosing two weeks later (Day 29).

Monitoring to Assess Safety

Prior to initiating YUFLYMA and periodically during therapy, evaluate patients for active tuberculosis and test for latent infection [see Warnings and Precautions (5.1)].

General Considerations for Administration

YUFLYMA is intended for use under the guidance and supervision of a physician. A patient may self-inject YUFLYMA or a caregiver may inject YUFLYMA using either the YUFLYMA AI or YUFLYMA prefilled syringe if a physician determines that it is appropriate, and with medical follow-up, as necessary, after proper training in subcutaneous injection technique.

YUFLYMA can be taken out of the refrigerator for about 15 to 30 minutes before injecting to allow the liquid to come to room temperature. Do not remove the cap or cover while allowing it to reach room temperature. Do not shake. Carefully inspect the solution in the YUFLYMA AI or YUFLYMA prefilled syringe for particulate matter and discoloration prior to subcutaneous administration. If particulates and discolorations are noted, do not use the product. YUFLYMA does not contain preservatives; therefore, discard unused portions of drug remaining from the syringe.

Instruct patients using the YUFLYMA AI or YUFLYMA prefilled syringe to inject the full amount in the syringe, according to the directions provided in the Instructions for Use [see Instructions for Use].

Injections should occur at separate sites in the thigh or abdomen. Rotate injection sites and do not give injections into areas where the skin is tender, bruised, red or hard.

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.